Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | PIM1 | P11309 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ELANE | P08246 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140417 | 0.95 | EGFR (0.60) | EGFRPIM1MEN1KMT2AALDH1A1 | |
| SCHEMBL13881117 | 0.86 | ELANE (0.52) | EGFRPIM1MEN1KMT2AALDH1A1 | |
| SCHEMBL13881116 | 0.86 | ELANE (0.52) | EGFRPIM1MEN1KMT2AALDH1A1 | |
| SCHEMBL3417492 | 0.84 | EGFR (0.76) | EGFRPIM1MEN1KMT2AALDH1A1 | |
| SCHEMBL11147739 | 0.81 | ALDH1A1 (0.70) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16226477 | 0.81 | ELANE (0.68) | EGFRPIM1MEN1KMT2AALDH1A1 | |
| SCHEMBL8505898 | 0.81 | ALDH1A1 (0.58) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL7792566 | 0.81 | EGFR (0.71) | EGFRPIM1MEN1KMT2AALDH1A1 | |
| SCHEMBL16076625 | 0.80 | ELANE (0.55) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL612831 | 0.79 | MAPT (0.74) | EGFRPIM1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059067-A1 | 1-ACETYL-5-HYDROXYANTHRACENE-9,10-DIONE FOR TREATMENT OF RETINAL DISEASE | CHARLESSON, LLC (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120059067-A1 | 1-ACETYL-5-HYDROXYANTHRACENE-9,10-DIONE FOR TREATMENT OF RETINAL DISEASE | CHARLESSON, LLC (US) | 2012-03-08 | — | — | US | disclosed |
| US-8058316-B2 | STAT3 inhibiting compositions and methods | CHARLESSON, LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058316-B2 | STAT3 inhibiting compositions and methods | CHARLESSON, LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110077306-A1 | STAT3 INHIBITING COMPOSITIONS AND METHODS | CHARLESSON, LLC (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077306-A1 | STAT3 INHIBITING COMPOSITIONS AND METHODS | CHARLESSON, LLC (US) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077306-A1 | STAT3 INHIBITING COMPOSITIONS AND METHODS | STAT3, STAT1, STAT5B | EGFR 1350/4885PIM1 1180/4885MEN1 4872/4885 |
| US-20120059067-A1 | 1-ACETYL-5-HYDROXYANTHRACENE-9,10-DIONE FOR TREATMENT OF RETINAL DISEASE | ACAT1, ACAT2, LCLAT1 | EGFR 2052/4885PIM1 4715/4885MEN1 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.